Evidence map›Paper›PMID 27388622›Full record

ArticleIn silico pharmacology2016

Classification model of amino acid sequences prone to aggregation of therapeutic proteins.

Monika Marczak, Krystyna Okoniewska, Tomasz Grabowski

Open access · hybridAbstract read
In one paragraph

Article in In silico pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Monika MarczakDofarm, ul. Aksamitna 15, 05-870, Błonie, Poland.
Krystyna OkoniewskaP.F.O. Vetos-Farma sp. z o. o., ul. Dzierżoniowska 21, 58-260, Bielawa, Poland. krystyna.okoniewska@vetos-farma.com.pl.
Tomasz GrabowskiPolpharma Biologics, ul.Trzy lipy 3, 80-172, Gdańsk, Poland.
For farmers (United Kingdom) · GBSciencePharma (Poland) · PLUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTotal body clearance of biological drugs is for the most part dependent on the receptor mechanisms (receptor mediated clearance) and the concentration of antibodies aimed at administered drug - anti-drug-antibodies (ADA). One of the significant factors that induces the increase of ADA level after drug administration could be the aggregates present in the finished product or formed in the organism. Numerous attempts have been made to identify the sequence fragments that could be responsible for forming the aggregates - aggregate prone regions (APR). PURPOSE: The aim of this study was to find physiochemical parameters specific to APR that would differentiate APR from other sequences present in therapeutic proteins.

methodsTwo groups of amino acid sequences were used in the study. The first one was represented by the sequences separated from the therapeutic proteins (n = 84) able to form APR. A control set (CS) consisted of peptides that were chosen based on 22 tregitope sequences.

resultsClassification model and four classes (A, B, C, D) of sequences were finally presented. For model validation Cooper statistics was presented.

conclusionsThe study proposes a classification model of APR. This consists in a distinction of APR from sequences that do not form aggregates based on the differences in the value of physicochemical parameters. Significant share of electrostatic parameters in relation to classification model was indicated.

Indexed as

ADAAggregatesImmunogenicityIn silicoProteins

Identifiers

PMID27388622
PMCPMC4937009
OpenAlexW2470122104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.